ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2025

HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With

John V Heymach et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.